OUR COMPANY
Genetic Testing
Making Ophthalmic Diagnosis More Complete
Pioneer in Genetic Diagnosis
Avellino is a biotech company providing
genetic diagnostics for eye disease based on
research and development and is expanding its
scope into various eye disease tests, including
corneal dystrophy.
genetic diagnostics for eye disease based on
research and development and is expanding its
scope into various eye disease tests, including
corneal dystrophy.
Dedication to Accurate Results
Avellino provides the world’s first commercially
available TGFBI corneal dystrophy genetic test.
Through the fast, accurate, and reliable genetic tests
offered by Avellino, ophthalmologists and patients
continuously receive precise test results.
available TGFBI corneal dystrophy genetic test.
Through the fast, accurate, and reliable genetic tests
offered by Avellino, ophthalmologists and patients
continuously receive precise test results.
History
2008
- Founded
2009
- Patent application for Avellino Corneal Dystrophy Genetic Test
2010
- Established branches and started services in four regions of Japan
(Tokyo, Osaka, Nagoya, Fukuoka)
2011
- Established U.S. Corporation
2012
- Acquired CLIA certificate for U.S. Corporation
2014
- Received the Minister of Future Creation and Science Commendation
2015
- Selected as a Technology Pioneer at the Davos Forum
- Avellino Korea launched Universal Test
2022
- Surpassed 1 million genetic tests for corneal dystrophies
Avellino Network
Based on extensive experience in genetic testing,
Avellino is expanding
its genetic diagnostic capabilities
to ophthalmology field worldwide.
Avellino is expanding
its genetic diagnostic capabilities
to ophthalmology field worldwide.
Contact
info.kr@avellino.ai
